Loading…
Employees: 4,493
Size Menicon (7780.T) is a Japan Health Care company (Medical Specialties) with a market value of $854M, the 813th largest of 1,379 Japan companies the cockpit tracks. Shares closed at ¥1,816 on 6 Nov 2026.
Performance Over six months the shares gained 12.1%, against -13.3% for the median peer and +1.8% for the Japan market (cap-weighted) — 6th highest of 21 in its peer set.
Growth Revenue grew 5.0% over the last twelve months (peer median +8.1%); the operating margin is 9.2% (peer median 9.6%).
Valuation It trades at 19.3× forward earnings against a peer median of 22.1× (8th cheapest of 17).
Capital Return on invested capital runs 0.6 points above its cost of capital (5.0% WACC).
Next results Next results expected around 13 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥128B | ¥126B | ¥121B | ¥116B | ¥110B |
| Revenue growth | — | +3% | +5% | +5% | — |
| Gross profit | ¥69.1B | ¥67.6B | ¥65.1B | ¥61.0B | ¥58.5B |
| EBITDA | ¥22.7B | ¥21.1B | ¥18.5B | ¥16.9B | ¥19.5B |
| Net income | ¥7.16B | ¥5.92B | ¥5.60B | ¥4.54B | ¥7.38B |
| Free cash flow | n/a | -¥3.37B | -¥77.0M | -¥8.24B | ¥1.31B |
| Capital expenditure | n/a | ¥16.5B | ¥17.5B | ¥21.3B | ¥13.0B |
| Total debt | ¥81.5B | ¥74.2B | ¥75.1B | ¥70.8B | ¥53.6B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 7780.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.9% | -3.6% | 7th highest of 21 |
| 6-month return | +12.1% | -13.3% | 6th highest of 21 |
| Distance from 52-week high | -12.9% | -34.7% | 5th highest of 21 |
| Revenue growth (TTM) | +5.0% | +8.1% | 10th lowest of 21 |
| Operating margin | 9.2% | 9.6% | 10th lowest of 21 |
| Forward P/E | 19.3× | 22.1× | 8th cheapest of 17 |
| ROIC minus cost of capital | +0.6 pp | +1.1 pp | 10th lowest of 21 |
| EV / EBITDA | 8.0× | 12.3× | 3rd cheapest of 11 |
| Net debt / EBITDA | 2.1× | -0.2× | 2nd most indebted of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Menicon 7780.T | Japan | $854M | +12% | +5% | 9% | 19.3× | n/a | n/a |
| Beta Bionics BBNX | United States | $854M | +63% | +44% | -73% | n/a | n/a | n/a |
| Zylox-Tonbridge Medical Technology 2190.HK | Hong Kong | $851M | -13% | +39% | 25% | 15.9× | 5.5% | +105.8% |
| MedCap MCAP.ST | Sweden | $864M | +6% | +17% | 15% | 26.4× | 2.9% | +20.9% |
| JINS 3046.T | Japan | $865M | -12% | +14% | 10% | 16.6× | -7.2% | +11.7% |
| Sino Medical Sciences Technology 688108.SS | China | $868M | -35% | +22% | 19% | 69.2× | 31.0% | +9.9% |
| Modern Dental 3600.HK | Hong Kong | $871M | +19% | +12% | 22% | 8.8× | -7.0% | +11.3% |
| Beijing Aerospace Changfeng 600855.SS | China | $832M | -35% | -10% | -19% | n/a | n/a | n/a |
| OrthoPediatrics KIDS | United States | $829M | +78% | +16% | -8% | n/a | n/a | n/a |
| Hangzhou Biotest Biotech 688767.SS | China | $824M | +5% | -4% | 3% | 34.7× | n/a | n/a |
| Advanced Medical Solutions AMS.L | United Kingdom | $824M | +14% | +6% | 12% | 20.7× | 19.6% | +21.4% |
| Cisen Pharmaceutical 603367.SS | China | $890M | -15% | -6% | 8% | 8.3× | -12.9% | -1.3% |
| Safilo SFL.MI | Italy | $890M | +24% | -4% | 9% | 16.0× | -0.5% | +4.7% |
| Bioventus BVS | United States | $894M | +1% | +4% | 10% | 13.1× | 6.9% | +12.1% |
| Maccura Biotechnology 300463.SZ | China | $814M | -14% | -1% | -4% | 164.7× | 9.2% | -10.2% |
| Shanghai Aladdin Biochemical Technology 688179.SS | China | $806M | -25% | +39% | 26% | 30.0× | 21.1% | +24.2% |
| Mani 7730.T | Japan | $909M | -15% | +10% | 30% | 18.4× | 1.5% | +13.9% |
| Shanghai Runda Medical Technology 603108.SS | China | $909M | -25% | -12% | -2% | 25.1× | 22.2% | -0.2% |
| Beijing SDL Technology 002658.SZ | China | $910M | -21% | -13% | 9% | 23.6× | 18.0% | +2.9% |
| LifeTech Scientific 1302.HK | Hong Kong | $914M | -18% | +1% | 12% | 23.5× | 13.3% | +15.5% |
| Allmed Medical Products 002950.SZ | China | $798M | -39% | +14% | 8% | n/a | n/a | n/a |